Spots Global Cancer Trial Database for VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
Official Title: Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy
Study ID: NCT03400176
Conditions
Study Description
Brief Summary: Patients enrolled to the study had chronic lymphocytic leukemia (CLL) and received ibrutinib. Patients have either received ibrutinib for one year without having had a complete response or patients developed a resistance mutation to ibrutinib. This study had two parts, a dose escalation part and a dose expansion part. Patients in the expansion part were enrolled into two arms depending on whether they had ibrutinib resistance mutations present at baseline.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California San Diego - Moores Cancer Center, La Jolla, California, United States
David Geffen School of Medicine at UCLA David Geffen School of Med, Los Angeles, California, United States
Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State University, Columbus, Ohio, United States
Tennessee Oncology Centennial Medical Center, Nashville, Tennessee, United States
University of Utah / Huntsman Cancer Institute Oncology, Salt Lake City, Utah, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
